'''Cetraxate''' ([[International Nonproprietary Name|INN]]) is an oral [[gastrointestinal]] [[medication]] which has a cytoprotective effect.<ref name="pmid3367546">{{cite journal |vauthors=Kurebayashi Y, Ikeda T, Osada Y |title=Cytoprotective action of cetraxate against HCl.ethanol-induced gastric lesion in rats |journal=Jpn. J. Pharmacol. |volume=46 |issue=1 |pages=17–25 |date=January 1988 |pmid=3367546 |doi= 10.1254/jjp.46.17|url=http://joi.jlc.jst.go.jp/JST.Journalarchive/jphs1951/46.17?from=PubMed}}</ref> Double-blind clinical trials in patients with gastric ulcer compared the effects of cetraxate with those of the drug [[gefarnate]], a common standard drug treatment for gastric ulcer. Endoscopic examinations of patients treated with cetraxate showed cure rates of 28% after 4 weeks, 61% after 8 weeks, and 73% after 12 weeks of treatment, significantly higher than cure rates seen with gefarnate at both 8 and 12 weeks.<ref name="pmid391240">{{cite journal |vauthors=Ishimori A, Yamagata S, Taima T |title=Effect of p-hydroxyphenyl-propionic ester of tranexamic acid hydrochloride (Cetraxate) on peptic ulcer. Multi-center clinical study |journal=Arzneimittelforschung |volume=29 |issue=10 |pages=1625–32 |year=1979 |pmid=391240 |doi= |url=}}</ref>
